Confronto
Leuprorelin vs. Octreotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
53714-56-0
83150-76-9
Peso molecolare
1209.4 g/mol
1019.24 g/mol
Emivita
3 h
1.7 h
Sequenza
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtD-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Meccanismo d'azione
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
4
4
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
3
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Leuprorelin and Octreotide?
- Leuprorelin is classified as "Ricerca (altro)", while Octreotide is classified as "Ricerca (altro)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Octreotide?
- The highest available evidence level is "RCT sull'uomo" for Leuprorelin and "RCT sull'uomo" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Octreotide in Germany and the United States?
- Germania: Leuprorelin — Su prescrizione, Octreotide — Su prescrizione. Stati Uniti: Leuprorelin — Su prescrizione, Octreotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.